Findings from the Women's Health Initiative hormone study send the message that clinicians can feel confident prescribing menopausal hormone replacement therapy (MHT) to young menopausal women with moderate-to-severe symptoms who do not have absolute contraindications for hormone therapy. However, MHT is indicated for the alleviation of symptoms, not for chronic disease prevention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Davis, S. R. et al. Understanding weight gain at menopause. Climacteric 15, 419–429 (2012).
Rossouw, J. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomised Controlled Trial. JAMA 288, 321–333 (2002).
Lobo, R. A. Where are we 10 years after the Women's Health Initiative? J. Clin. Endocrinol. Metab. 98, 1771–1780 (2013).
Manson, J. E. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310, 1353–1368 (2013).
de Villiers, T. J. et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16, 316–337 (2013).
Geukes, M., van Aalst, M. P., Nauta, M. C. & Oosterhof, H. The impact of menopausal symptoms on work ability. Menopause 19, 278–282 (2012).
Mishra, G. D. & Dobson, A. J. Using longitudinal profiles to characterize women's symptoms through midlife: results from a large prospective study. Menopause 19, 549–555 (2012).
Connolly, B. S. et al. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr. Cancer 44, 127–138 (2002).
Reeves, G. K. et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335, 1134 (2007).
Stovall, D. W., Tanner-Kurtz, K. & Pinkerton, J. V. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms. Drugs 71, 1649–1657 (2011).
Acknowledgements
S. R. Davis would like to acknowledge the support of an NHMRC research grant (grant number 1041853).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S. R. D. has received research grant support from Lawley Pharmaceuticals and is a consultant for Trimel Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Davis, S. Hormone therapy to treat menopause—breaking a taboo. Nat Rev Endocrinol 10, 6–8 (2014). https://doi.org/10.1038/nrendo.2013.219
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.219
